Literature DB >> 24434958

[Medication-based therapy of infantile hemangioma and lymphatic malformations].

J Rössler1, F Braunschweiger, T Schill.   

Abstract

The therapy of vascular tumors and malformations should be interdisciplinary and performed according to available guidelines. Infantile hemangiomas (IH) are the most frequent vascular tumors of childhood and do not require treatment in most cases. If the IH is complicated by its location (e.g. facial or genital) or if the lesion threatens to cause loss of function, small localized IH should be treated by laser- or cryotherapy. If the IH is diffuse or rapidly growing it can be successfully treated using the β blocker propranolol. The mechanism underlying the efficacy of this medication-based therapy is not completely understood and this still represents an experimental therapy. The results of molecular studies on vascular malformations have indicated new strategies for medical therapies. However, lymphatic malformations (LM) are still treated by surgery where possible, or sclerotherapy. Further investigations are necessary to determine whether new drugs such as the mTOR inhibitor rapamycin may be effective for treatment of diffuse LM. First case reports seem to be promising.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24434958     DOI: 10.1007/s00106-013-2794-0

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  25 in total

1.  Interferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication.

Authors:  H Wörle; E Maass; B Köhler; J Treuner
Journal:  Eur J Pediatr       Date:  1999-04       Impact factor: 3.183

2.  Propranolol for severe hemangiomas of infancy.

Authors:  Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

Review 3.  Vascular tumors and vascular malformations (new issues).

Authors:  O Enjolras; J B Mulliken
Journal:  Adv Dermatol       Date:  1997

4.  Clusterin/apoJ expression during the development of hemangioma.

Authors:  Q Hasan; B M Rüger; S T Tan; J Gush; P F Davis
Journal:  Hum Pathol       Date:  2000-06       Impact factor: 3.466

5.  Complications of systemic corticosteroid therapy for problematic hemangioma.

Authors:  L M Boon; D M MacDonald; J B Mulliken
Journal:  Plast Reconstr Surg       Date:  1999-11       Impact factor: 4.730

6.  Sirolimus for the treatment of complicated vascular anomalies in children.

Authors:  Adrienne M Hammill; MarySue Wentzel; Anita Gupta; Stephen Nelson; Anne Lucky; Ravi Elluru; Roshni Dasgupta; Richard G Azizkhan; Denise M Adams
Journal:  Pediatr Blood Cancer       Date:  2011-03-28       Impact factor: 3.167

7.  25 years' experience with lymphangiomas in children.

Authors:  A Alqahtani; L T Nguyen; H Flageole; K Shaw; J M Laberge
Journal:  J Pediatr Surg       Date:  1999-07       Impact factor: 2.545

Review 8.  Head and neck lymphatic malformation treatment: a systematic review.

Authors:  Mary Theresa Adams; Babette Saltzman; Jonathan A Perkins
Journal:  Otolaryngol Head Neck Surg       Date:  2012-07-11       Impact factor: 3.497

9.  Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.

Authors:  S Huber; C J Bruns; G Schmid; P C Hermann; C Conrad; H Niess; R Huss; C Graeb; K-W Jauch; C Heeschen; M Guba
Journal:  Kidney Int       Date:  2007-02-14       Impact factor: 10.612

10.  Propranolol for severe infantile hemangiomas: follow-up report.

Authors:  Véronique Sans; Eric Dumas de la Roque; Jérôme Berge; Nicolas Grenier; Franck Boralevi; Juliette Mazereeuw-Hautier; Dan Lipsker; Elisabeth Dupuis; Khaled Ezzedine; Pierre Vergnes; Alain Taïeb; Christine Léauté-Labrèze
Journal:  Pediatrics       Date:  2009-08-10       Impact factor: 7.124

View more
  2 in total

1.  Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.

Authors:  Denise M Adams; Cameron C Trenor; Adrienne M Hammill; Alexander A Vinks; Manish N Patel; Gulraiz Chaudry; Mary Sue Wentzel; Paula S Mobberley-Schuman; Lisa M Campbell; Christine Brookbank; Anita Gupta; Carol Chute; Jennifer Eile; Jesse McKenna; Arnold C Merrow; Lin Fei; Lindsey Hornung; Michael Seid; A Roshni Dasgupta; Belinda H Dickie; Ravindhra G Elluru; Anne W Lucky; Brian Weiss; Richard G Azizkhan
Journal:  Pediatrics       Date:  2016-01-18       Impact factor: 7.124

2.  Sirolimus for treatment of kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon.

Authors:  Alaa M Alaqeel; Nuha A Alfurayh; Alanoud A Alhedyani; Saad M Alajlan
Journal:  JAAD Case Rep       Date:  2016-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.